BERTANI; Barbara

Patent Applications and Registrations

Patent applications and USPTO patent grants for BERTANI; Barbara.The latest application filed is for "cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide".

Company Profile

4.16.25

BERTANI; Barbara - Castiglione delle Stiviere IT
Bertani; Barbara - Verona IT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cyclic Ether Derivatives Of Pyrazolo[1,5-a]pyrimidine-3-carboxyamide App 20210032259 - HOENKE; Christoph ; et al.	2021-02-04
Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide Grant 10,875,867 - Hoenke , et al. December 29, 2	2020-12-29
Cyclic Ether Derivatives Of Pyrazolo[1,5-a]pyrimidine-3-carboxyamide App 20200039991 - HOENKE; Christoph ; et al.	2020-02-06
Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide Grant 10,479,794 - Hoenke , et al. Nov	2019-11-19
Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide Grant 10,023,575 - Hoenke , et al. July 17, 2	2018-07-17
Cyclic Ether Derivatives Of Pyrazolo[1,5-a]pyrimidine-3-carboxyamide App 20180134720 - HOENKE; Christoph ; et al.	2018-05-17
Cyclic Ether Derivatives Of Pyrazolo[1,5-a]pyrimidine-3-carboxyamide App 20170101411 - HOENKE; Christoph ; et al.	2017-04-13
Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders Grant 9,085,584 - Giovannini , et al. July 21, 2	2015-07-21
Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament Grant 9,012,489 - Giovannini , et al. April 21, 2	2015-04-21
4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes App 20140045857 - GIOVANNINI; Riccardo ; et al.	2014-02-13
4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes App 20140045856 - GIOVANNINI; Riccardo ; et al.	2014-02-13
Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament App 20130197011 - GIOVANNINI; Riccardo ; et al.	2013-08-01
Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D.sub.3 receptors Grant 8,222,266 - Bertani , et al. July 17, 2	2012-07-17
Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine D.sub.3 receptors Grant 8,217,168 - Bertani , et al. July 10, 2	2012-07-10
Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors Grant 8,178,549 - Bertani , et al. May 15, 2	2012-05-15
Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors Grant 8,163,927 - Bertani , et al. April 24, 2	2012-04-24
Spirocompounds useful as modulators for dopamine D3 receptors Grant 8,030,322 - Bertani , et al. October 4, 2	2011-10-04
Azabicyclo [3. 1. 0] Hexyl Derivatives As Modulators Of Dopamine D3 Receptors App 20100240661 - Bertani; Barbara ; et al.	2010-09-23
Azabicyclo [3. 1. O] Hexyl Derivatives As Modulators Of Dopamine D3 Receptors App 20100210672 - Bertani; Barbara ; et al.	2010-08-19
Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors App 20100204273 - Bergauer; Markus ; et al.	2010-08-12
Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors Grant 7,732,600 - Bergauer , et al. June 8, 2	2010-06-08
Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione Grant 7,727,988 - Bertani , et al. June 1, 2	2010-06-01
Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors App 20100069416 - Bertani; Barbara ; et al.	2010-03-18
Azabicyclo [3.1.0] Hexane Derivatives as Modulators of Dopamine D3 Receptors App 20100063097 - Bertani; Barbara ; et al.	2010-03-11
Spirocompounds Useful As Modulators For Dopamine D3 Receptors App 20100063078 - Bertani; Barbara ; et al.	2010-03-11
Azabicyclic Compounds As Inhibitors Of Monoamines Reuptake App 20100035914 - Bertani; Barbara ; et al.	2010-02-11
5-quinolinone Derivatives As 5ht1a Receptor Modulators For Treating Sexual Dysfunction, Cognition Impairment, Psychotic Disorders, Anxiety, Depression, Etc. App 20100004452 - Bertani; Barbara ; et al.	2010-01-07
Quinoline And Quinazoline Derivatives Having Affinity For 5ht1-type Receptors App 20090312546 - BERGAUER; Markus ; et al.	2009-12-17
Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors Grant 7,592,346 - Bergauer , et al. September 22, 2	2009-09-22
Benzoxazinone Derivatives, Preparation Thereof And Uses In The Treatment Of Cns And Other Disorders App 20090076274 - Bertani; Barbara ; et al.	2009-03-19
Quinoline And Quinazoline Derivatives Having Affinity For 5ht1-type Receptors App 20080280919 - Bergauer; Markus ; et al.	2008-11-13
Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione App 20070249642 - Bertani; Barbara ; et al.	2007-10-25
Quinoline And Quinazoline Derivatives Having Affinity For 5ht1-type Receptors App 20070167423 - Bergauer; Markus ; et al.	2007-07-19
Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders App 20060264429 - Bertani; Barbara ; et al.	2006-11-23
Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors App 20060229312 - Bergauer; Markus ; et al.	2006-10-12
Tetrahydroquinolines as NMDA antagonists Grant 5,977,136 - Di Fabio , et al. November 2, 1	1999-11-02

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.